Illumina to buy Solexa for $600M

Illumina has agreed to buy Solexa, which makes genetics analysis systems, for $600 million. Illumina will also provide $50 million for Solexa, which specializes in whole genome sequencing. Illumina says it will maintain Solexa's operations in California and Cambridge, England. Solexa CEO John West becomes a senior vice president in the combined life science research firm.

- here's the report on the buyout from MarketWatch

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.